OXO-imidazolidines as modulators of chemokine receptors
申请人:Chemocentryx, Inc.
公开号:US07786157B2
公开(公告)日:2010-08-31
The present invention provides compounds having formula (I):
or pharmaceutically acceptable salts and N-oxides thereof, wherein the subscript m is an integer from 0-4; Ar is an optionally substituted aryl; B is an optionally substituted aryl; L1 is an optionally substituted linking group selected from the group consisting of C1-4 alkylene, C1-4 heteroalkylene, C2-4 alkenylene and —CH2N(Ru)X5—; and L2 is a bond or C1-3 alkylene. The compounds act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity.
OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS
申请人:Zhang Penglie
公开号:US20080269280A1
公开(公告)日:2008-10-30
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.